Combined assessment of carotid intima–media thickness and epicardial fat thickness for cardiovascular risk stratification in asymptomatic South Indian adults - Scorecard - MDSpire
Clinical Scorecard: Evaluation of Carotid Intima-Media Thickness and Epicardial Fat Thickness for Cardiovascular Risk Assessment in Asymptomatic Adults from South India
At a Glance
Category
Detail
Condition
Cardiovascular Risk Assessment
Key Mechanisms
Carotid intima-media thickness (cIMT) and epicardial fat thickness (EFT) as non-invasive imaging markers linked to cardiovascular risk.
Target Population
Asymptomatic adults aged ≥18 years with or without cardiovascular risk factors.
Care Setting
Routine cardiovascular health evaluations.
Key Highlights
Participants with cardiovascular risk factors had significantly higher cIMT and EFT compared to controls.
Abnormal cIMT prevalence increased with age, from 2.2% in those under 40 to 28.0% in those over 60.
Hypertension, diabetes mellitus, and dyslipidaemia were significantly associated with increased cIMT and EFT.
Mean left cIMT was modestly but significantly higher than mean right cIMT.
Cumulative cardiovascular risk-factor burden correlated with progressively higher cIMT and EFT values.
Guideline-Based Recommendations
Diagnosis
Utilize carotid ultrasonography for cIMT measurement.
Employ transthoracic echocardiography for EFT assessment.
Management
Incorporate cIMT and EFT in cardiovascular risk stratification alongside traditional risk factors.
Monitoring & Follow-up
Monitor changes in cIMT and EFT in patients with known cardiovascular risk factors.
Risks
Increased cIMT and EFT are associated with higher cardiovascular risk and potential future events.
Patient & Prescribing Data
Asymptomatic adults undergoing routine cardiovascular health assessments.
Consider the role of cIMT and EFT in identifying subclinical atherosclerosis for preventive interventions.
Clinical Best Practices
Use non-invasive imaging markers to enhance cardiovascular risk assessment.
Regularly evaluate asymptomatic adults for cardiovascular risk factors.
In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.
